DDInter1042 DDInter36
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Albiglutide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Albiglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liotrix
Albiglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thyroid, porcine
Albiglutide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Albiglutide may cause a minor interaction that can limit clinical effects when taken with Warfarin
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Albiglutide may lead to a major life threatening interaction when taken with Bexarotene